Voru

Researchers are evaluating the safety and effectiveness of contezolid acefosamil (administered intravenously) and contezolid (administered orally) compared to linezolid (administered both intravenously and orally) in adults with moderate or severe diabetic foot infections (DFI). This Phase 3, multicenter, randomized, double-blind study involves approximately 865 adult subjects whose infections are confirmed or suspected to be caused by Gram-positive bacteria. The study focuses on helping understand treatment responses in this population with diabetes-related foot infections. Participants will receive either contezolid acefosamil/contezolid or linezolid for a total treatment duration of 14 to 28 days, with dosing ranging from 28 to 56 doses in total. Both treatments are given through intravenous and oral routes during this period. The study groups are compared for their effects on the infection and safety outcomes during and after this treatment phase. During the study, participants will be monitored for clinical response by assessing the resolution of infection signs and symptoms without needing further therapy by Day 35. Safety evaluations include tracking adverse events reported by participants, clinical laboratory tests such as complete blood counts, and vital signs like heart rate between 28 and 35 days after the end of therapy. This comprehensive monitoring helps assess both the effectiveness and safety of the treatments over the study timeline.